At the same time , EFS and OS in 14-to-18-year-old adolescents were statistically significantly higher than in those who used MePRED ( EFS , 656 and 526 % , respectively ( p = 0.087 ) ; OS , 726 and 616 % , respectively ; ( p = 0 .